CD274 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs) of programmed cell death‐1/programmed cell death‐ligand 1 (PD‐1/PD‐L1) inhibitors, such as pembrolizumab, nivolumab, and atezolizumab, have been approved for advanced NS‐NSCLC because of their substantial improvements in survival compared with chemotherapy.31, 32, 33, 34